Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.

S Dewilde, Beth Woods, JG Castaigne, C. Parker, W. Dunlop

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)111-124
JournalJournal of Medical Economics
Issue number2
Early online date13 Jan 2014
Publication statusPublished - 2014

Cite this